THE EFFECTS OF IMMUNIZATION WITH XENOGENEIC EMBRYO PROTEINS ON LYMPHOCYTES FUNCTIONS IN MICE BEARING LEWIS LUNG CARCINOMA
DOI:
https://doi.org/10.32471/oncology.2663-7928.t-23-4-2021-g.9894Keywords:
chicken embryo proteins, Lewis lung carcinoma, lymphocytes functioning, xenogeneic cancer vaccineAbstract
Different types of cancer vaccines are elaborated so far and researches in this field are going on. In this experiment, chicken embryo proteins (CEP) as a potential source of antigens for a future xenogeneic vaccine was utilized. Aim: to investigate the effects of CEP on lymphocytes’ activity in mice bearing Lewis lung carcinoma (LLC). Object and Methods: C57Bl male mice were immunized on days 1, 8, and 15 after challenge with LLC cells. The immune response was assessed on days 7, 14, 21 and 28 after tumor transplantation. Cytotoxic activity of natural killer (NK) cells and cytotoxic T-lymphocytes as well as antibody dependent cellular cytotoxicity (ADCC) was estimated in MTT-assay; interferon γ, interleukin (IL)-4, IL-10 levels in the blood serum were detected in ELISA; lymphocyte proliferation was studied in reaction of in vitro blast transformation. Results: in mice bearing LLC tumor, immunization with CEP increased NK, cytotoxic T-lymphocytes and ADCC cytotoxic activities, as well as raised the level of lymphocytes blast-transformation in response to LLC-antigens. Our findings indicate that CEP showed activating effects on lymphocytes, providing an insight into the potential of CEP to elicit anticancer immune response. CEP proved to be a feasible source of antigens which can be utilized in xenogeneic cancer vaccines engineering. Conclusion: it was shown that CEP immunization positively influenced lymphocytes activity in mice bearing LLC tumor eliciting both specific and innate anticancer immune responses. NK cells may play a front role in the activation processes induced by immunization with CEP.
References
Pan RY, Chung WH, Chu MT, et al. Recent development and clinical application of cancer vaccine: targeting neoantigens. J Immunol Res 2018; 19:2018:4325874. https://www.hindawi.com/journals/jir/2018/4325874/.
Cavallo F, Aurisicchio L, Mancini R, Ciliberto G. Xenogene vaccination in the therapy of cancer. Expert Opin Biol Ther 2014; 14: 1427–42.
Symchych TV, Fedosova NI, Karaman OM, et al. Anticancer effectiveness of vaccination based on xenogeneic embryo proteins applied in different schedules. Experim Oncol 2015; 37: 197–202.
Symchych TV, Fedosova NI, Karaman OM, et al. Anticancer effect and immunologic response to xenogeneic embryonic proteins in mice bearing Ehrlich solid carcinoma. Experim Oncol 2017; 39: 42–8.
Kozhemyakin YM, Khromov OS, Filonenko MA, Sayfutdinova HA. Guideline on management of laboratory animals and work with them. Kyiv: Avitsena, 2002. 179 p. (in Ukrainian).
Isokawa K, Rezaee M, Wunsch A, et al. Identification of transferrin as one of multiple EDTA-extractable extracellular proteins involved in early chick heart morphogenesis. J Cell Biochem 1994; 54: 207–18.
van de Loosdrecht AA, Beelen RHJ, Ossenkoppele GJ, et al. A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. J Immunol Met 1994; 174: 311–20.
Whiteside TL. Antigen/mitogen-stimulated lymphocyte proliferation. In: Lotze MT, Thomson AW, eds. Measuring immunity: Basic biology and clinical assessment. Elsevier Academic Press, 2005: 361–8.
Schutt C. Reaction of blast-transformation (LBTR) in clinical diagnostic. In: Friemel H, ed. Immunological methods. Moscow: Mir, 1979: 487–500.
Butterfield LH. Cancer vaccines. BMJ 2015; 350: h988. doi: 10.1136/bmj.h988.
Pawelec G. Immune correlates of clinical outcome in melanoma. Immunol 2017; 153: 415–22.
Martín-Fontecha A, Thomsen LL, Brett S, et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(h)1 priming. Nat Immunol 2004; 5: 1260–5.
Lotze MT. Interleukin-1 family of cytokines and cancer. In: Caligiuri MA, Lotze MT, eds. Cytokines in the genesis and treatment of cancer. Humana Press, 2007: 113–34.
Wong JL, Mailliard RB, Moschos SJ, et al. Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells. J Immunother 2011; 34: 270–8.
Kalinski P, Giermasz A, Nakamura Y, et al. Helper role of NK cells during the induction of anticancer responses by dendritic cells. 2005; 42: 535–9.
Zingoni A, Sornasse T, Cocks BG, et al. Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions. J Immunol 2004; 173: 3716–24.
Sivori S, Pende D, Bottino C, et al. NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. Eur J Immunol 1999; 29: 1656–66.
Pietra G, Manzini C, Vitale M, et al. Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. Int Immunol 2009; 21: 793–801.
Moretta L, Bottino C, Pende D, et al. Surface NK receptors and their ligands on tumor cells. Semin Immunol 2006; 18: 151–8.
Senju H, Kumagai A, Nakamura Y, et al. Effect of IL-18 on the expansion and phenotype of human natural killer cells: application to cancer immunotherapy. Int J Biol Sci 2018; 14: 331–40.
Smyth MJ, Swann J, Kelly JM, et al. NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer. J Exp Med 2004; 200: 1325–35.
Symchych TV, Fedosova NI, Karaman OM, et al. The anticancer efficiency of the xenogeneic vaccine and the indication for its use. Exp Oncol 2014; 36: 79–84.
